Wine and the properties of resveratrol: what science says

Editorial Note
This article was previously published and has been updated according to scientific and divulgative criteria. Informational purpose: it does not replace medical advice. The references cited are verifiable via DOI in the final section "Scientific Research".

In brief

• Resveratrol is a polyphenol found in many plants, notably in grapes and red wine.
• Studies in rodents provide evidence that resveratrol can promote the "browning" of white fat (formation of beige fat) and improve certain metabolic parameters [1][2].
• In humans, the evidence is heterogeneous: some small trials suggest effects on vascular function or specific markers; meta-analyses report modest or no results on weight and metabolic markers [4][5][6][7].
• The observational association between moderate alcohol consumption (including wine) and less weight gain in some cohorts does not prove causality and should be evaluated in the context of the overall risk associated with alcohol [3].

Abstract: what does science say?

Resveratrol is a natural compound studied for its possible antioxidant, anti-inflammatory, and metabolic effects. In animal models, it has shown the ability to improve insulin sensitivity, increase mitochondrial activity, and promote the conversion of white fat to beige fat, leading to reduced weight gain on high-calorie diets. However, in human clinical studies, the results are conflicting: some trials report improvements in vascular function or muscular transcriptional changes, while several meta-analyses do not confirm clear effects on weight, lipids, or glycemia. Translating the dosages used in the laboratory to the quantities obtainable with wine is problematic due to bioavailability and safety reasons. In summary, the evidence suggests plausible mechanisms but not a general recommendation for the use of wine or resveratrol supplements for the prevention or treatment of metabolic diseases.

What is resveratrol and where is it found?

Resveratrol is a polyphenol from the stilbene family produced by various plants as a response to biotic or abiotic stress. In the human diet, it is present in grapes, berries, and in varying amounts in red wine due to contact with the skins during winemaking. Like many polyphenols, it is a biologically active compound in the laboratory: it shows antioxidant capabilities and interactions with intracellular metabolic pathways relevant to inflammation and energy metabolism. However, the amount of resveratrol in individual foods is very low compared to the experimental doses often used in cell and animal studies. Therefore, talking about the "effect of wine" means combining a possible molecular contribution with other factors of the dietary and lifestyle model; it does not automatically mean that drinking wine produces the same effects observed with concentrated or formulated doses of resveratrol.

Experimental evidence: biological mechanisms and adiposity

Preclinical research has highlighted mechanisms through which resveratrol can influence energy metabolism: activation of AMPK, modulation of SIRT1 and PGC‑1α, increase in mitochondrial number, and promotion of lipid oxidation. Studies in mice have shown that dietary resveratrol supplementation can shift the physiology of animals fed high-calorie diets towards profiles similar to those of animals on controlled diets and, in some cases, reduce weight gain and improve insulin sensitivity [2]. In parallel, research conducted by groups such as Washington State University has documented that resveratrol can promote the formation of "beige" adipocytes from white adipose tissue, a phenomenon known as "browning," with a potential increase in local energy dissipation [1]. These effects are biologically plausible and support the hypothesis that some polyphenols may contribute to modulating energy balance; however, the question of their clinical relevance at realistic human doses and forms of intake remains open.

The three types of fat and the concept of "browning"

In the human body, white fat (energy reserve), brown fat (thermogenesis through UCP1-rich mitochondria), and beige fat, an intermediary that can emerge within white tissue in response to stimuli, are classically recognized. "Browning" indicates the differentiation of cells with thermo-active characteristics; promoting it is an experimental goal to combat obesity. Experimental observations indicate that natural compounds, including resveratrol, can modulate molecular pathways involved in this process, but the demonstration of a clinically significant effect in humans is not yet consolidated.

Clinical evidence in humans: trials and observational studies

In recent years, clinical studies of various sizes and quality have been conducted to evaluate the effects of resveratrol in humans. Small randomized crossover trials have shown conflicting results: some report improvements in vascular function or changes in gene expression and mitochondrial number in skeletal muscles, without consistent effects on glycemia, weight, or lipid profile [5][4]. A series of meta-analyses and reviews have evaluated the available data: overall, the syntheses indicate modest or no effects on many cardiometabolic markers, with occasionally favorable results for individual outcomes at certain doses or in subgroups, but without robust evidence of benefit on weight loss [6][7][8]. The role of observational studies should also be noted: a cohort of almost 19,220 women followed longitudinally showed that moderate alcohol consumers (including wine) tended to gain less weight than abstainers; however, these are associations that may reflect behavioral differences, diets, and other confounding factors and not a direct causal relationship [3].

Risks, bioavailability, and translation from experimental doses

Two fundamental points limit interpretation: the bioavailability of resveratrol and the dose difference between experimental studies and actual dietary consumption. Resveratrol has rapid metabolism and low plasma concentration after oral intake, which reduces the likelihood that the small content present in wine reaches the levels used in many studies. Furthermore, effective dosages in animal models would be difficult to achieve through wine consumption without exceeding safety limits related to alcohol. Finally, some recent studies explore formulations or vehicles (e.g., nanoparticles) to improve delivery to adipose tissue, but such approaches are still experimental [1][9].

What it means in practice

The evidence suggests that resveratrol is a molecule of interest for research on metabolic mechanisms and aging. In practical terms for the general public: moderate wine consumption is not a proven strategy for weight loss or disease prevention; the benefits observed in populations or in the laboratory do not authorize starting to drink for health reasons. Public health recommendations remain focused on limiting alcohol consumption, balanced dietary choices, and regular physical activity. For those considering resveratrol supplements, it is advisable to consult a doctor: product quality, dosage, drug interactions, and possible adverse effects are not uniformly regulated.

Key points to remember

• Mechanisms: Resveratrol interacts with cellular pathways involved in metabolism and mitochondria (e.g., AMPK, SIRT1).
• Animals: In murine models, it has shown favorable effects on metabolism and lifespan under certain conditions [2].
• Humans: Clinical results are heterogeneous; some studies show vascular or transcriptional effects, but evidence on weight and glycemia is weak or inconsistent [4][5][6].
• Quantity: Effective doses in the laboratory are generally much higher than those obtainable by drinking wine.
• Risk vs. benefit: Alcohol consumption carries known risks (cancer, addiction, liver damage); the choice regarding wine consumption must consider the individual risk profile.

Limitations of the evidence

It is important to distinguish between study types and methodological limitations. Observational studies (cohorts) can show associations but not prove causality: differences in lifestyle or unmeasured factors can explain the results. Experimental studies in vitro or in animals help identify mechanisms but do not guarantee clinical effects in humans at realistic doses. Clinical trials in humans exist, often with small samples, short durations, variable doses, and different formulations; these heterogeneities complicate meta-analyses. Furthermore, the low bioavailability of resveratrol and possible drug interactions necessitate caution in interpretation and clinical translation.

Editorial conclusion

Resveratrol remains an interesting scientific target with plausible mechanisms for modulating metabolism and inflammation. Preclinical evidence is solid for initiating research, but human clinical evidence does not justify simplistic claims or public health recommendations based on wine consumption or the systematic use of supplements. Individual choices should be based on a balance between potential benefits and known risks; the path to effective translation into therapies or recommendations requires larger clinical studies, well-characterized dosages, and long-term safety evaluation.

Editorial Note

The article is an update of a previous text; the information has been reviewed based on peer-reviewed studies and systematic reviews. The information provided is for informational purposes only and does not replace personal medical advice.

Scientific Research

1. Songbo Wang, et al. Resveratrol induces brown‑like adipocyte formation in white fat through activation of AMP‑activated protein kinase (AMPK) α1. International Journal of Obesity. 2015. https://doi.org/10.1038/ijo.2015.23 [1]
2. Baur JA, et al. Resveratrol improves health and survival of mice on a high‑calorie diet. Nature. 2006. https://doi.org/10.1038/nature05354 [2]
3. Lu Wang, et al. Alcohol consumption, weight gain, and risk of becoming overweight in middle‑aged and older women. Archives of Internal Medicine. 2010. https://doi.org/10.1001/archinternmed.2009.527 [3]
4. Sanne M. van der Made, Jogchum Plat, Ronald P. Mensink. Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo‑controlled crossover trial. PLoS One. 2015. https://doi.org/10.1371/journal.pone.0118393 [4]
5. Jill P. Crandall, et al. Resveratrol treatment in older adults with impaired glucose regulation: randomized, double‑blind, placebo‑controlled crossover study. The Journals of Gerontology: Series A. 2017. https://doi.org/10.1093/gerona/glx041 [5]
6. Efficacy and Safety of Resveratrol Supplements on Blood Lipid and Blood Glucose Control in Patients with Type 2 Diabetes: a systematic review and meta‑analysis. Diabetes Research and Clinical Practice. 2019. https://doi.org/10.1016/j.diabres.2019.107843 [6]
7. Meta‑analysis: Effects of resveratrol supplementation on risk factors of non‑communicable diseases. Critical Reviews in Food Science and Nutrition. 2017. https://doi.org/10.1080/10408398.2017.1349076 [7]
8. Systematic review and meta‑analysis: What is the effect of resveratrol on obesity? Clinical Nutrition ESPEN. 2020/2021. https://doi.org/10.1016/j.clnesp.2020.11.025 [8]
9. de Ligt M., et al. Resveratrol supplementation reduces ACE2 expression in human adipose tissue. Endocrine (or related journal). 2021. https://doi.org/10.1080/21623945.2021.1965315 [9]
10. RESTORE Trial: Effect of resveratrol on walking performance in older people with peripheral artery disease. JAMA Cardiology. 2017. https://doi.org/10.1001/jamacardio.2017.0538 [10]

Note: the bibliography lists the verified DOIs for the cited studies. For complete documents, please consult the corresponding DOI link for full access and metadata.